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Abstract
Influenza A viral polymerase is a heterotrimeric complex that consists of PA, PB1, and PB2 subunits. We previously reported
that a di-codon substitution mutation (G507A-R508A), denoted J10, in the C-terminal half of PA had no apparent effect on
viral RNA synthesis but prevented infectious virus production, indicating that PA may have a novel role independent of its
polymerase activity. To further examine the roles of PA in the viral life cycle, we have now generated and characterized
additional mutations in regions flanking the J10 site from residues 497 to 518. All tested di-codon mutations completely
abolished or significantly reduced viral infectivity, but they did so through disparate mechanisms. Several showed effects
resembling those of J10, in that the mutant polymerase supported normal levels of viral RNA synthesis but nonetheless
failed to generate infectious viral particles. Others eliminated polymerase activity, in most cases by perturbing the normal
nuclear localization of PA protein in cells. We also engineered single-codon mutations that were predicted to pack near the
J10 site in the crystal structure of PA, and found that altering residues K378 or D478 each produced a J10-like phenotype. In
further studies of J10 itself, we found that this mutation does not affect the formation and release of virion-like particles per
se, but instead impairs the ability of those particles to incorporate each of the eight essential RNA segments (vRNAs) that
make up the viral genome. Taken together, our analysis identifies mutations in the C-terminal region of PA that differentially
affect at least three distinct activities: protein nuclear localization, viral RNA synthesis, and a trans-acting function that is
required for efficient packaging of all eight vRNAs.
Citation: Liang Y, Danzy S, Dao LD, Parslow TG, Liang Y (2012) Mutational Analyses of the Influenza A Virus Polymerase Subunit PA Reveal Distinct Functions
Related and Unrelated to RNA Polymerase Activity. PLoS ONE 7(1): e29485. doi:10.1371/journal.pone.0029485
Editor: Paul Digard, University of Cambridge, United Kingdom
Received September 9, 2011; Accepted November 29, 2011; Published January 6, 2012
Copyright:  2012 Liang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health (NIH) grant R01AI067704. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: yliang5@emory.edu
¤a Current address: Department of Microbiology, Mount Sinai School of Medicine, New York, New York, United States of America
¤b Current address: The Arcas Group, LLC, Norcross, Georgia, United States of America
¤c Current address: Department of Veterinary and Biomedical Sciences, University of Minnesota, St Paul, Minnesota, United States of America
Introduction
The RNA-dependent RNA polymerase of influenza A virus is a
heterotrimeric protein complex comprised of three virally-encoded
subunits, designated PA, PB1, and PB2 [1,2]. Localized within the
nuclei of infected host cells, this polymerase trimer is essential for
synthesizing all influenza RNA species. Its functions include
replication of the eight different uncapped, non-polyadenylated,
negative-sense RNA segments (vRNAs) that make up the viral
genome, and of the positive-sense replicative intermediates known
as cRNAs. It also transcribes all viral mRNAs, using a
biochemically distinct process that is initiated through polymer-
ase-mediated cap-snatching from host mRNAs and yields capped,
polyadenylated viral transcripts [1]. The polymerase is also a key
structural constituent of influenza virion particles, within which a
single polymerase trimer is believed to be associated stably with
each of the packaged vRNAs, binding simultaneously to its paired
39 and 59 ends [3,4]. This stable binding of one polymerase trimer
onto each vRNA occurs within the host-cell nucleus and, together
with the binding of viral nucleoprotein (NP) and other factors,
gives rise to a ribonucleoprotein complex [5], which serves as the
substrate for nucleocytoplasmic export, intracellular trafficking,
and packaging of the vRNAs into nascent virions.
Biochemical and genetic studies of the polymerase subunits have
helped delineate the roles that each of these proteins plays in viral
RNA synthesis. PB2 has a cap-binding motif that binds to the 59
caps of host-cell mRNAs [6,7]. PB1 has RNA-dependent RNA
polymerase activity and binds to the conserved terminal sequences
of the vRNA and cRNA [8,9,10]. PA has been shown to interact
directly with the PB1 subunit of the intact trimer complex, and
plays an essential role in viral RNA synthesis [11,12,13,14,
15,16,17,18,19]. PA consists of two domains connected by a linker
[20]. Although no full-length structure of PA has yet been
reported, the high-resolution structures of its two halves in
isolation provide numerous insights, including atomic-level details
of the binding interactions between its C-terminal domain and the
PB1 subunit in the trimeric polymerase complex, as well as the
unexpected discovery that the cap-endonuclease enzymatic site
resides within its N-terminal domain [21,22,23,24]. These
structural findings offer a new context in which to revisit data
from earlier mutational studies that probed the functional topology
of PA.
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substitution mutant designated J10, involving residues G507 and
R508 in the C-terminal half of the protein, whose phenotype
unexpectedly suggested that PA has a key role in viral replication
unrelated to polymerase activity [19]. In particular, the J10
mutant appeared to have little or no effect on synthesis of any of
the three classes of viral RNA, yet it completely abolished the
production of infectious virions [19]. In this study, we have carried
out further mutational analysis of regions that lie near J10 in the
known crystallographic structure of C-terminal PA. Our studies
yielded groups of mutants with distinct phenotypic defects. One set
of PA mutants proved defective in nuclear localization, which
presumably accounts for their lack of RNA polymerase activity.
Other mutants lacked polymerase enzymatic function despite
being properly localized. Still others exhibited a J10-like
phenotype, in that they abolished viral infectivity without any
apparent effect on viral RNA synthesis. On further analysis of J10
itself, we found that this mutation does not affect the production or
release of virus-like particles but instead decreases viral RNA
packaging into these particles. Our studies thus reveal that
mutations within the C-terminal domain of PA can differentially
affect PA localization, viral polymerase activity, and a third, novel
function related to viral RNA packaging.
Materials and Methods
Cells
Cell lines were obtained from American Type Culture
Collection (ATCC). 293T (human epithelial kidney cells) cells
were grown in Dulbecco’s modified Eagle’s medium (DMEM with
high glucose) supplemented with 10% heat-inactivated fetal bovine
serum (FBS). Madin-Darby canine kidney (MDCK) and Madin-
Darby bovine kidney (MDBK) cells were maintained in Eagle’s
minimal essential medium (MEM) supplemented with 5% FBS.
After infection with either influenza virus or viral-like particles
(VLPs), MDCK and MDBK cells were grown in L-15 medium
containing 15 mM HEPES, pH7.5, nonessential amino acids,
0.75 g of NaHCO3 per liter, and 0.125% (w/v) of bovine serum
albumin.
Plasmids
The 17-plasmid [25] influenza A virus reverse genetic systems
were obtained from Y. Kawaoka (University of Wisconsin). The
luciferase reporter construct cNA-LUC was previously described
[19]. PA 66-G-50, PB1 66-G-50, and PB2 0-G-100 are GFP
reporter constructs carrying packaging signals from the PA, PB1,
and PB2 vRNAs, respectively, and have been described elsewhere
[26]. Mutations of the PA gene were created by PCR-based
mutagenesis on pHH21-PA using primers containing the intended
changes. The protein-expression vectors encoding each PA mutant
were generated by PCR amplification of the PA open-reading
frame from the corresponding pHH21-PA constructs and cloned
into the pcDNA3.1 vector. Primer sequences will be provided
upon request. All mutations were confirmed by DNA sequencing.
Generation of influenza A viruses harboring PA
mutations
293T cells in 6-well plates were transfected with 17 plasmids
together to generate infectious influenza A/WSN viruses [25],
including either the wild-type (WT) pHH21-PA vector one of its
mutant counterparts, using TransIT-LT1 transfection reagent
(Panvera, Madison, Wisconsin) according to the manufacturer’s
protocol and as described before [19]. Cell media were replaced at
6 h post-transfection with Opti-MEM containing 0.3% BSA and
0.01% FBS. Supernatants were collected at 48 h post-transfection
for virus titer determination by plaque assay.
Evaluation of viral RNA transcription in a 5-plasmid
transfection system
293T cells were transfected with 0.1 mg of the LUC reporter
construct cNA-LUC [19], together with 0.25 mg of each of the
protein-expression vectors encoding PB2, PB1, and NP, and with
0.25 mg of the protein-expression vector encoding either WT or
mutant PA protein. A b-galactosidase (b-gal) expression plasmid
(Invitrogen) was included as an internal control for normalizing
transfection efficiency. At 24 h post-transfection, cells were
harvested for LUC assay and normalized to b-gal activity. LUC
activity and b-gal activity were measured using firefly LUC assay
system (Promega) and b-gal enzyme assay system (Promega),
respectively.
Evaluation of viral RNA synthesis by primer-extension
assay
The 5-plasmid assay was conducted as described above. Total
RNA was harvested from the transfected cells and analyzed by the
established primer extension assay for the level of three viral RNA
species, cRNA, vRNA, and mRNA. In brief, strand-specific
primers were 59-end-labeled with [gamma-
32P]ATP and annealed
with total RNAs for reverse transcription. The primer extension
products (with expected lengths of 75 nt for vRNA, 85 nt for
cRNA, and 93–96 nt for mRNA) were precipitated and separated
on a 10% urea-denaturing polyacrylamide gel. The gel was dried
and autoradiographed.
Generation of replication-defective viral-like particles
(VLPs)
293T cells were transfected with the 17 plasmids required to
generate replication-competent virions, except that either the WT
or the J10-mutant forms of both the protein- and vRNA-encoding
vectors for PA were included, and with one vRNA-expression
vector (PA, PB1 or PB2) replaced by a vector encoding the
corresponding packaging-competent GFP construct PA-GFP (PA
66-G-50), PB1-GFP (PB1 66-G-50) or PB2-GFP (PB2 0-G-100).
For metabolic labeling, the transfected cells were pre-incubated
with media containing dialyzed FBS for 30 min prior to the
addition of
35S labeling mix (PerkinElmer). After 24 h, the
supernatants were collected, filtered through 0.45 mM filters, and
enriched for VLPs using either chicken erythrocytes or polyclonal
anti-H1N1 antiserum (Fitzgerald Inc., MA). The corresponding
cell lysates were prepared and immunoprecipitated with anti-
H1N1 antiserum. Enriched VLPs from the supernatants or the
viral proteins in the cell lysates were then analyzed by SDS-PAGE
and detected by autoradiography.
To quantify packaging efficiency, VLPs were prepared without
metabolic labeling. At 48 h post-transfection, supernatants from
transfected 293T cells were collected, filtered through 0.45 mM
filters, and then used either for flow cytometric analysis or for real-
time RT-PCR quantification. For flow cytometric analysis,
aliquots of supernatants were used to infect MDCK cells, together
with helper A/WSN virus at moi of 0.1. The GFP-transferring
units per ml were then determined by flow cytometric analysis of
the infected MDCK cells at 18 hpi.
Quantitation of VLP-incorporated vRNA segments by
real-time RT-PCR
We incubated transfection supernatants with 1 ml of micrococ-
cal nuclease at 37uC for 30 minutes, prior to extracting viral RNA
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possible plasmid DNA contamination by incubating samples for
30 min at 37uC with DNase I, which was then inactivated by
heating samples to 85uC for 15 min. Reverse transcription was
conducted using influenza-specific primer and the SuperScript III
first-strand synthesis system (Invitrogen). Quantitative real-time
PCR was performed in a 20-ml reaction with gene-specific primers
as described previously [27]. Primer sequences will be provided
upon request.
Results
Mutational analysis of residues 497–518 of PA in viral
infectivity
We have reported that the bi-codon mutation J10 (G507A-
R508A) in PA has little or no apparent effect on viral RNA synthesis
but severely impairs infectivity and viral particle yield in a
spreading-infection assay [19]. This implied a novel function for
PA protein in the viral life cycle, whose exact nature was unknown.
Though located within the C-terminal domain, J10 does not
coincide with the PB1-interaction site or other functional residues
mapped previously in this domain [13,14,21,22,28,29]. We
therefore created additional scanning mutations to interrogate the
regions flanking the J10 site. As in our earlier study, each was a di-
codon substitution mutation designed to replace a pair of
consecutive residues with alanines; a total of 10 mutants (designated
L1–L10) were created that together scanned residues 497–518 of
PA (Table 1). Western blot analysis confirmed that, when plasmids
encoding these mutants were transiently expressed in 293T cells,
each of the eight mutants yielded protein of comparable size and
abundancetowild type PA(Figure1A). When recombinantviruses
carrying thesemutations were assembledinthe 17-plasmidA/WSN
system, however, only L1 and L8 were able to support plaque
formation, with a greatly reduced virus titer observed for L8
(Table 1). All other mutations yielded no detectable plaque-
forming virus, apart from rare wild-type revertants. Both L1- and
L8-containing viruses produced small, cloudy plaques (Figure 1B),
and showed delayed growth kinetics as compared to wild type
(Figure 1C), suggesting that each had a partial defect in spreading
infection. Collectively, these results reveal that mutations through-
out a 21-amino-acid region (residues 497–518) in PA protein that
includes the J10 site can impair viral infectivity.
Mutational analysis of residues 497–518 of PA in viral
RNA synthesis
We then used a well-established 5-plasmid transfection assay to
determine whether any of the foregoing PA mutations affected
RNA-synthesisactivityofthe viralpolymerase trimer.Forthisassay,
293T cells are transfected transiently with plasmids that encode,
respectively, a luciferase-reporter vRNA and the four influenza
proteins (PA, PB1, PB2, and NP) that are minimally required to
replicate and transcribe it. When used in place of wild-type PA in
the 5-plasmid assay (Figure 2A), five mutants (L3, L5, L8, L9, and
L10) were able to support luciferase expression at levels comparable
to that of the wild type. By contrast, mutant L7 supported only
,15% of wild-type luciferase expression, and mutants L1, L2, L4,
and L6 showed little or none, indicating that polymerase complexes
containing any of the latter five mutants are defective in RNA
synthesis. That conclusion was directly confirmed by the results of a
primer-extension assay that directly quantifies the levels of all three
viral RNA species produced from the luciferase reporter in these
same cells (Figure 2B). In the primer-extension assay, cells that
expressed mutants L3, L5, L8, L9, and L10 each produced levels of
vRNA, cRNA, and mRNAcomparable to those seen with wild-type
PA, whereas mutants L1, L2, L4, L6, and L7 were defective in
production of all three RNA species. Taken together, these results
demonstrate that whereas some of the mutations within this region
ofPA that disable infectivity areassociated withimpairedviralRNA
synthesis, others, like J10, are not.
Table 1. Rescue of recombinant viruses with mutations
within residues 497–518 of PA.
Virus Mutations Plaque Titer Plaque Morphology
WT 1.0E+6 Large, Clear
L1 K497A, T498A 3.4E+5 Small, unclear
L2 N499A, L500A 0 N/A
L3 Y501A, G502A 0 N/A
L4 F503A, I504A 0 N/A
L5 I505A, K506A 0 N/A
L6 S509A, H510A 0 N/A
L7 L511A, R512A 0 N/A
L8 N513A, D514A 7.2E+3 Small, unclear
L9 T515A, D516A 0 N/A
L10 V517A, V518A 0 N/A
N/A, not applicable.
doi:10.1371/journal.pone.0029485.t001
Figure 1. Mutational analysis of residues 497–518 of PA on
viral growth. (A) Expression level of the PA mutants in the transfected
293T cells was analyzed by western blot analysis using anti-PA
polyclonal antibody. (B) Plaque formation on MDCK cells by wild-type
(WT), recombinant mutant L1 (K497A, T498A), and L8 (N513A, D514A).
(C) Growth curve analysis of WT, L1, and L8 on MDCK cells at moi of
0.001.
doi:10.1371/journal.pone.0029485.g001
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Because all synthesis of influenza viral RNAs takes place within
the nucleus, we asked whether any of our five PA mutations that
abolished RNA polymerase activity did so by interfering with the
normal nuclear localization of the polymerase trimer complex. To
that end, we used a PA-specific monoclonal antibody (3G5,
generously provided by Dr. Peter Palese) to observe the subcellular
localization of PA through indirect immunofluorescence. In 293T
cells that had been transiently transfected with a PA-protein-
expression vector alone, we found that PA was exclusively
cytoplasmic (Figure 3). When co-expressed along with PB1 and
PB2, however, PA was found exclusively in the nucleus, in keeping
with earlier evidence that nuclear retention of PA depends mainly
on its physical interaction with other polymerase subunits,
particularly PB1 [30,31,32,33]. We found that, like wild-type
PA, the J10, L6, and L10 mutants also localized within the nucleus
when co-expressed with PB1 and PB2, but that the L1, L2, and L4
mutants remained in the cytoplasm, and that L7 was distributed in
both compartments (Figure 3). This indicates that the defective
activity of polymerases containing the L1, L2, L4, or possibly L7
mutants of PA is associated with defective nuclear localization,
whereas the polymerase defect produced by mutation L6 occurs
independently of any evident localization defect. Of note, L10 and
J10, representing the class of mutants that severely impair
infectivity without affecting RNA synthesis, both exhibited the
wild-type pattern of nuclear localization
Mutational analysis of PA residues 361–480
Guided by the published crystallographic structure of the PA C-
terminal domain [21,22], we then engineered additional point
mutants targeting residues that are relatively distant from J10 in
the primary sequence but pack close to it in the folded native state.
We targeted eight individual residues within positions 361–480, in
each case substituting alanine for a single charged, polar, or bulky
native residue (i.e., K361, K362, K367, E372, K378, K385, D478,
and F480); in addition, we recreated the mutant E656A which had
been reported by other investigators to form tiny plaques despite
normal viral RNA synthesis [13], a phenotype reminiscent of J10.
Each of these mutants was then used in place of wild-type PA in
the 17-plasmid virus-assembly system (Table 2). Consistent with
the earlier report, E656A yielded a virus titer more than 2 logs
lower than wild type, and it formed tiny plaques (Figure 4A).
K378A gave indistinct plaques and a 25-fold reduced titer, and
D478A produced a mixture of large and small plaques. None of
the other tested mutants had a substantial effect on plaque titer or
morphology (Table 2 and Figure 4A).
Further characterization of these mutants was obtained through
growth-curve analysis on MDCK cells (Figure 4B). At 20 hpi,
when wild-type virus had reached a titer of 10
6 pfu/ml, the titers
Figure 2. Mutational analysis of residues 497–518 of PA on
viral RNA synthesis. (A) The effects of PA mutants on viral RNA
synthesis were analyzed in a 5-plasmid system. Fold induction of
luciferase activity over the control was shown in log scale. Results
shown are the average of at least 3 independent experiments with error
bars representing standard deviation. (B) The levels of all three viral
RNA species were analyzed by primer extension assay.
doi:10.1371/journal.pone.0029485.g002
Figure 3. Nuclear localization of PA constructs. COS1 cells were transfected with expression vector of wild-type or mutant PA proteins, with or
without (-PB1, -PB2) expression vectors of PB1 and PB2. Immunofluorescence analysis was conducted to detect the PA protein by monoclonal
antibody 3G5 (kindly provided by Dr. Palese, Mount Sinai), with nucleus stained with DAPI.
doi:10.1371/journal.pone.0029485.g003
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E656A was not yet producing detectable plaques. At 28 hpi, titers
of E656A and K378A each lagged the wild-type by ,50 fold,
while that of D478A lagged by 300 fold. The growth of all three
mutants lagged by 20–1,000 fold at 40 hpi. The remaining
mutants had only minor defects, associated with ,10-fold
decreased growth throughout the infection.
When tested for polymerase activity using the 5-plasmid assay,
E656A was the only mutant in this group that showed any defect,
as evidenced by modest reductions both in luciferase expression
and in RNA synthesis as measured by the primer-extension assay
(Figure 4C). In summary, among this group of nine single-codon
mutations targeting residues that lie close to the J10 locus in the
native PA structure, we found two (K378A and D478A) that
markedly reduced infectivity without compromising RNA synthe-
sis – the phenotype shared by L3, L5, L8, L9, and L10, and first
observed in J10.
The J10 mutation does not inhibit influenza virus-like
particle assembly
Our initial characterization of J10 had shown that it imparts a
profound quantitative defect in influenza particle production in a
spreading-infection assay, where the yield of particles is normally
amplified exponentially by cell-to-cell transmission. To determine
the effect of J10 on virus production in individual cells, we
therefore examined its properties in a single-round transfection
assay, where transmission does not occur. This was achieved by
using a modified 17-plasmid transfection assay to generate non-
infectious virus-like particles (VLPs) in which one of the native
vRNAs was replaced by a packaging-competent vRNA reporter
that encoded GFP; these VLPs could be released into the
supernatant and quantified by their ability to transduce GFP into
MDCK cells, but were incapable of initiating new rounds of
infection. We have previously reported three such GFP-reporter
vRNAs, derived from the PA, PB1, and PB2 vRNAs, respectively,
that are incorporated into virion particles with efficiencies
comparable to those of the wild-type vRNAs [26]. For the present
study, we assembled VLPs that incorporated each of these three
Table 2. Rescue of recombinant viruses with single alanine
substitution in the C-terminal region of PA.
Virus Mutations Plaque Titer Plaque Morphology
WT 1.0E+6 Large, Clear
L11 E656A 9.40E+03 Small, unclear
L12 K361A 2.80E+06 Large
L13 K362A 7.60E+05 Large
L14 K367A 6.00E+05 Large
L15 E372A 1.32E+06 Large
L16 K378A 3.80E+04 Medium, unclear
L17 K385A 2.20E+06 Large
L18 D478A 2.60E+05 Mixture
L19 F480A 2.00E+05 Large
doi:10.1371/journal.pone.0029485.t002
Figure 4. Characterization of additional single alanine substitution at charged or bulky residues in the C-terminal region. (A) Plaque
formation on MDCK cells. Effects of PA mutations on the polymerase activity. (B) Growth curve analysis of recombinant viruses on MDCK cells at moi
of 0.001. (C) The effects of PA mutants on viral RNA synthesis were analyzed in a 5-plasmid system. Fold induction of luciferase activity over the
control was shown in log scale. Results shown are the average of at least 3 independent experiments with error bars representing standard deviation.
The levels of all three viral RNA species were analyzed by primer extension assay.
doi:10.1371/journal.pone.0029485.g004
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expression vector, in the presence of either wild-type PA or the
J10 mutant. The results described below were substantially
identical regardless of which reporter construct was used.
To assay VLP production and composition, we incubated
producer 293T cells continuously with
35S-MetCys after transfec-
tion with the 17-plasmid system, then harvested both cell lysates
and supernatants at 24 h, enriched VLPs from the supernatants
using density-sedimentation followed either by immunobead
precipitation with polyclonal anti-H1N1 antiserum or by hemag-
glutination on chicken erythrocytes, and then analyzed the
constituent proteins by SDS-PAGE and autoradiography. As
shown in Figure 5A, biosynthetically radiolabelled NP, M1, and
other proteins were readily detectable in producer-cell lysates that
had been immunoprecipitated by anti-H1N1 antiserum; as
expected, their concentrations remained similar regardless of
whether a PA, PB1, or PB2 vRNA reporter had been transfected,
and regardless of whether the wild-type PA protein-expression
vector or its J10 mutant was used. When we then analyzed the
corresponding VLP-enriched supernatants (Figure 5B) from
these various transfectants, we again detected several radiolabelled
proteins of presumably viral origin (indicated by arrows), and
again found that their concentrations did not differ appreciably
between J10 and wild-type PA transfectants, regardless of the
vRNA reporter used. These data indicate that the J10 and wild-
type PA proteins can each support the production and release of
VLPs, in roughly comparable amounts and with apparently
similar protein compositions.
Table 3. Real time quantitative analysis of RNA segments in
VLPs.
PB2-GFP PB1 PA NP HA NA M NS
WT 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
J10 17.0% 16.0% 39.0% 46.0% 7.0% 39.0% 5.7% 53.0%
Results shown are representative data of two experiments.
doi:10.1371/journal.pone.0029485.t003
Figure 5. PA J10 mutant does not affect the formation of VLPs but decreases viral RNA packaging efficiency. The 293T cells were
transfected with the 17-plasmid system to reconstitute the replication-defective VLPs, in which a full-length vRNA construct was replaced with a
corresponding vRNA segment that encodes GFP and is packaged efficiently (PA-GFP, PB1-GFP, and PB2-GFP) [26], with either the WT or J10 mutant
PA (for both the RNA and protein-encoding vectors). The cells were metabolically labeled with
35S for 24 h. (A) Cell lysates were immunoprecipitated
with anti-H1N1 antiserum and separated by SDS-PAGE. The most abundant viral proteins, M1 and NP, are highlighted by arrows. C, negative control
of which the PA plasmids were omitted from the transfection. (B) Supernatants were VLP-enriched by either chicken erythrocytes or anti-H1N1
antiserum and separated by SDS-PAGE. Only the chicken erythrocytes enriched VLPs are showing here. The viral proteins are highlighted by arrows. C,
negative control of which the PA plasmids were omitted from the transfection. (C) Comparison of WT and J10 PA proteins in reporter vRNA
packaging. The supernatants containing the replication-defective VLPs, prepared in the absence of metabolic labeling, were collected at 48 h post-
transfection and used to infect fresh MDCK cells, with the helper virus at moi of 0.1. The infected MDCK cells were analyzed by flow cytometry for GFP
expression at 18 hpi. The GFP-transferring unit per ml is shown.
doi:10.1371/journal.pone.0029485.g005
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influenza vRNAs
We then asked whether the wild-type and J10-containing VLPs
differed in their ability to package viral RNAs. As an initial test, we
prepared VLP-containing 293T transfection supernatants as
described in the preceding section, but without radiolabelling.
Equivalent volumes of those supernatants were then used to infect
MDCK monolayers, with the addition of excess helper virus to
ensure that functional influenza polymerase activity was expressed
in the target cells. Flow cytometry was then used as described
[26,27] to enumerate GFP-expressing MDCK cells, and the yield
of GFP-positive cells per ml of transfection supernatant was
calculated as a measure of the efficiency with which the VLPs
packaged and transduced each vRNA reporter.
As depicted in Figure 5C, this GFP transduction assay
indicated that, for each of the three vRNA reporters we tested,
J10-containing VLPs packaged vRNA significantly less efficiently
than did their wild-type counterparts. The extent of the apparent
packaging defect (expressed as the ratio of wild-type to J10
transductants) was estimated in this assay as 2, 7, and 6 fold,
respectively, for the PA, PB1, and PB2 reporters (Figure 5C).
Because the results of the transduction assay could potentially be
influenced by events in the target cells, however, we sought to
verify and extend these findings through direct analysis of VLPs.
To that end, we prepared VLPs containing either wild-type or J10
PA, in the presence of the PB2 vRNA GFP reporter, enriched
these particles by sucrose-gradient centrifugation, and digested
them with micrococcal nuclease to remove any contaminating,
unpackaged RNA. We then extracted RNA from these VLP
preparations and assayed the concentrations of individual,
authentic, packaged vRNAs using real-time quantitative PCR
[34]. As shown in Table 3, we found that the GFP reporter,
which served as a proxy for PB2 vRNA, was packaged only 17%
as efficiently by J10-containing particles as by wild-type VLPs,
corresponding to the ,6-fold decrease in GFP transduction
(Figure 5C). The mutant particles, moreover, also proved
defective in packaging each of the seven authentic vRNAs, when
compared to wild-type particles, exhibiting relative packaging
efficiencies that ranged from 53% and 46% for the NS and NP
segments, respectively, to as low as roughly 6–7% for the HA and
M segments (Table 3). These data strongly suggest that the J10
mutation causes a generalized defect in the packaging efficiency of
all eight influenza vRNA segments.
Discussion
Our previous discovery of a novel, lethal phenotype for mutant
J10 (G507A-R508A) in the C-terminal half of PA [19] raised the
possibility that PA protein plays another essential role in influenza
biology that is unrelated to viral RNA synthesis. The residues
altered by this J10 mutation lie in a region of the C-terminal
domain that does not clearly coincide with other known functional
regions, such as the endonuclease active site and PB1-interacting
domain (Figure 6A). In the present study, we have examined a
new panel of alanine substitutions designed to interrogate residues
situated near the J10 site in the primary sequence or the native
folded conformation of PA (mutational effects are summarized in
Table 4). Our analyses provide several insights into structure-
function relationships in this essential influenza protein.
Several mutations we tested (i.e., L1, L2, L4, L6, and L7)
abolished most or all of the RNA synthetic activity of polymerase
complexes that contained them, impairing the production of all
three classes of influenza RNAs. Further inspection revealed that
the polymerase defects of L1, L2, and L4 are associated with a
failure of nuclear localization of PA, even in the presence of wild-
type PB1 and PB2 proteins. Previous research has indicated that
PA nuclear localization is dependent upon its interaction with PB1
[32], presumably during or after assembly of the polymerase
heterotrimer. Although the residues altered by the L1, L2, and L4
mutations are not part of the PA-PB1 protein interface that was
identified in a recent co-crystal structure (Figure 6B) it should be
noted that this structure included only the first 15 residues of PB1
[21,22]; hence, these three mutations might signify a second,
separate contact surface for full-length PB1 or, alternatively, might
influence some other aspect of polymerase complex assembly. The
L6 mutant (S509A, H510A), by contrast, localizes normally but
profoundly impairs viral RNA synthesis, suggesting an effect on
polymerase activity per se. This is consistent with a previous study
[35] showing that insertion of a single serine between residues
S509 and H510, which are normally exposed together on the
surface of PA (Figure 6C), yielded a dominant-negative PA
mutant that suppressed viral RNA production.
Of particular note, we have also identified several other mutants
that recapitulate the phenotype of J10, in that they dramatically
reduce or eliminate viral infectivity without impairing the ability of
the viral polymerase complex to replicate or transcribe viral RNAs.
Our finding that at least eight additional, non-overlapping
mutations (i.e., L3, L5, J10, L8, L9, L10, K378, and D478) all
share these properties serves to validate our initial description of the
phenotype, confirms that it is not unique to J10, and suggests the
existence of a ‘‘J10-like’’ functional domain that may extend over at
least 14 non-contiguous amino-acid residues in the PA protein.
When mapped to the crystal structure of the PA C-terminal region
(Figure 6A), those residues (with the exception of K378, which lies
in an ill-defined portion of the structure) cluster closely together and
Figure 6. Localization of the mutants on the PA 3-D structure.
The structure of the PA C-terminal region (PDB ID: 2ZNL) is shown in
magenta, with the bound PB1 peptide shown in blue. (A) Residues
corresponding to J10 and other J10-like mutants (L3, L5, L8, L9, L10, and
D478) are highlighted in yellow. K378 is not shown as it is localized to
an unresolved region. The position of J10 site is indicated by arrow. (B)
Residues corresponding to L1, L2, and L4 mutations, which affect PA
nuclear localization, are highlighted in yellow. (C) Residues of L6
mutant, which is localized to the nucleus but defective in all viral RNA
synthesis, are highlighted in yellow.
doi:10.1371/journal.pone.0029485.g006
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essential for the putative novel function of PA.
Using the J10 mutation as the prototype, we have further
demonstrated that this novel class of mutations does not affect the
yield or protein compositions of influenza VLPs in a single-round
assay, nor their release from cells (Figure 5B). Strikingly,
however, the particles assembled in the presence of J10 were
found to contain significantly reduced quantities of each of the
eight genomic RNA segments, regardless of whether those
segments were assayed by reporter transduction (Figure 5C)o r
by direct quantitation of individual, authentic vRNAs extracted
from VLPs (Table 3). The finding that all eight vRNAs are
affected implies a general role for PA in vRNA packaging. Indeed,
both the magnitude of the effect on any given vRNA, and the
extent of variation among vRNAs, are reminiscent of the
packaging defects that have been observed following certain
alterations of the vRNAs themselves. Importantly, although the
reduction in packaging of individual segments may appear modest,
their combined effects are fully sufficient, in principle, to account
for the severe infectivity defect we observe in J10-containing virus:
Assuming that the probability of packaging all eight vRNAs is
proportional to the product of their individual packaging
efficiencies, our data suggest that the relative likelihood of
acquiring a complete genome is (0.1760.1660.3960.4660.076
0.3960.0660.53=) approximately 4610
26 for J10-containing
VLPs, or roughly six orders of magnitude lower than for wild-type
influenza particles. These results therefore imply that PA is itself
an essential trans-acting factor for packaging influenza vRNAs.
Further studies will be needed to determine the mechanism by
which the putative ‘‘J10-like’’ region of the PA protein influences
vRNA packaging, as well as its potential as a target for new
antiviral drugs.
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Table 4. Mutational effects on viral infectivity and PA polymerase activity.
Mutants Residues
Infectivity
1
(virus titer at 20/28/40 hpi) RNA synthesis
2 PA localization
3
WT ++++/++++/++++ ++++ Nuc
J10 G507A, R508A 2 ++++ Nuc
L1 K497A, T498A 2/++/++ + Cyt
L2 N499A, L500A 2 ++ Cyt
L3 Y501A, G502A 2 ++++ n/a
L4 F503A, I504A 2 + Cyt
L5 I505A, K506A 2 ++++ Nuc
L6 S509A, H510A 22 Nuc
L7 L511A, R512A 2 +++ Nuc
L8 N513A, D514A 2/+/++ ++++ n/a
L9 T515A, D516A 2 ++++ n/a
L10 V517A, V518A 2 ++++ Nuc
L11 E656A 2/++/++ ++++ n/a
L12 K361A ++/++/++ ++++ n/a
L13 K362A +++/++/++ ++++ n/a
L14 K367A +++/++/+++ ++++ n/a
L15 E372A +++/+++/+++ ++++ n/a
L16 K378A +/++/++ ++++ n/a
L17 K385A ++/+++/+++ ++++ n/a
L18 D478A +/+/+ ++++ n/a
L19 F480A ++/++/++ ++++ n/a
1Infectivity of viable recombinant virus is defined by viral titers at 20, 28, and 40 hpi time points during viral growth kinetic analyses (Fig. 1C and Fig. 4B). ++++,W Ta n d
,0.5 log difference; +++, lower than WT by 0.5–1 log; ++, lower than WT by 1–2 log; +, lower than WT by .2 log; 2, no virus. If no viable virus is rescued, infectivity is
defined as 2.
2The level of RNA synthesis is determined by the 5-plasmid assay (Fig. 2 and Fig. 4C). ++++, .20% WT; +++, 2–20% WT; ++, 0.1–2% WT; +, ,0.1% WT; 2, no detectable
RNA synthesis.
3Subcellular localization of PA protein in the presence of PB1 and PB2 proteins (Fig. 3). Nuc, nucleus; Cyt, cytoplasm; n/a, data not available.
doi:10.1371/journal.pone.0029485.t004
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